{"id":26481,"date":"2020-10-27T06:47:00","date_gmt":"2020-10-27T06:47:00","guid":{"rendered":"http:\/\/4fc04a81635aa3bbcdb1f192235ccf0b"},"modified":"2024-11-03T15:16:15","modified_gmt":"2024-11-03T15:16:15","slug":"achieve-2-results-of-oxaliplatin-based-adjuvant-chemotherapy-in-asian-patients-with-high-risk-stage-ii-colon-cancer","status":"publish","type":"post","link":"https:\/\/ogkologos.com\/en\/achieve-2-results-of-oxaliplatin-based-adjuvant-chemotherapy-in-asian-patients-with-high-risk-stage-ii-colon-cancer\/","title":{"rendered":"ACHIEVE-2 Results of Oxaliplatin-Based Adjuvant Chemotherapy in Asian Patients with High-Risk Stage II Colon Cancer"},"content":{"rendered":"

The Asian researchers reported on 25 October 2020 in the Annals of Oncology<\/em> that 3-month of combination therapy for adjuvant treatment of high-risk stage II colon cancer resulted with significantly less grade \u22652 peripheral sensory neuropathy (PSN) than the 6-month regimen. The 3-month regimen did not affect the 3-year disease-free survival (DFS) rate. The ACHIEVE-2 (Adjuvant Chemotherapy for colon cancer with HIgh EVidencE in high-risk stage 2) researchers concluded that a 3-month course of adjuvant CAPOX can be an option for high-risk stage II colon cancer.<\/p>\n

Oxaliplatin-based adjuvant chemotherapy is considered an option for patients with high-risk stage II colon cancer. However, many patients develop PSN during the 6 months of oxaliplatin-based adjuvant therapy, leading to treatment modification or discontinuation. The incidence of long-lasting PSN is significantly lower with 3-month therapy than with 6-month therapy, and significantly lower with CAPOX than with mFOLFOX6.<\/p>\n

The phase III ACHIEVE-2 study of 3 versus 6 months of mFOLFOX6\/CAPOX adjuvant therapy for high-risk stage II colon cancer was conducted to assess the potential implications in reducing the adjuvant therapy duration to 3 months for Asian patients. One of the key objectives of the ACHIEVE-2 study was to provide data pertaining to Asian patients for the International Duration Evaluation of Adjuvant (IDEA) chemotherapy pooled analysis to investigate the non-inferiority of 3 versus 6 months of FOLFOX or CAPOX adjuvant chemotherapy.<\/p>\n

The IDEA pooled analysis for high-risk stage II colorectal cancer also collected data from three other phase III trials (SCOT [UK, Denmark, Spain, Sweden, Australia, and New Zealand], TOSCA [Italy], and HORG [Greece]) to compare the therapeutic effect (non-inferiority) of 3 months versus 6 months of adjuvant treatment in patients with high-risk stage II colon cancer worldwide.<\/p>\n

The ACHIEVE-2 was open-label, multicentre, randomised phase III study, a prospective pooled analysis conducted to investigate the non-inferiority of 3 versus 6 months of adjuvant oxaliplatin-based chemotherapy in stage II disease. From February 2014 to January 2017, 525 Asian patients with high-risk stage II colon cancer were randomly assigned to 3- and 6-month treatment arms. The treatment consisted of either mFOLFOX6 or CAPOX. The primary endpoint was DFS. The secondary endpoints were treatment compliance and safety.<\/p>\n

Of the 525 randomized patients, 11 were not treated. Among the 514 participating patients (255 in the 3-month arm; 259 in the 6-month arm), 432 (84%) received CAPOX. In total, 184 (36%) presented T4 as a high-risk factor for recurrence.<\/p>\n

The 3-year DFS rate was 88.2% in the 3-month arm and 87.9% in the 6-month arm (hazard ratio [HR] 1.12; 95% confidence interval [CI] 0.67\u20131.87). With CAPOX, the 3-year DFS rate was 88.2% in the 3-month arm and 88.4% in the 6-month arm (HR 1.13; 95% CI 0.65\u20131.96).<\/p>\n

The discontinuation rate in the 3- and 6-month arms was 10% and 31% for mFOLFOX6 (p = 0.0193), and 15% and 35% for CAPOX (p < 0.0001), respectively.<\/p>\n

The incidence of grade \u22652 PSN was significantly lower in the 3-month arm than in the 6-month arm, 16% and 43%, respectively (p < 0.0001).<\/p>\n

The authors concluded that a shorter duration of oxaliplatin-based adjuvant chemotherapy significantly reduced grade \u22652 PSN, and it did not compromise the DFS. However, this study was conducted as a part of the IDEA Collaboration trials and did not have the statistical power to independently determine the optimised adjuvant chemotherapy duration.<\/p>\n

Nevertheless, the data suggested that patients with high-risk stage II colon cancer, especially patients with non-T4 and high-risk stage II colon cancer, receiving oxaliplatin-based adjuvant chemotherapy can be considered for 3 months of CAPOX therapy as a treatment option with favourable risk\u2013benefit balance.<\/p>\n

Reference<\/h4>\n

Yamazaki K, Yamanaka T, Shiozawa M, et al.<\/em> Oxaliplatin-Based Adjuvant Chemotherapy Duration (3 vs. 6 Months) for High-Risk Stage II Colon Cancer: The Randomized Phase 3 ACHIEVE-2 Trial<\/a>. Annals of Oncology<\/em>; Published online 25 October 2020. DOI: https:\/\/doi.org\/10.1016\/j.annonc.2020.10.480<\/a>.<\/p>\n

Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The Asian researchers reported on 25 October 2020 in the Annals of Oncology that 3-month of combination therapy for adjuvant treatment of high-risk stage II colon cancer resulted with significantly less grade \u22652 peripheral sensory neuropathy (PSN) than the 6-month regimen. The 3-month regimen did not affect the 3-year disease-free survival (DFS) rate. The ACHIEVE-2 […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5137],"tags":[],"class_list":["post-26481","post","type-post","status-publish","format-standard","hentry","category-world-news"],"_links":{"self":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/26481","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/comments?post=26481"}],"version-history":[{"count":1,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/26481\/revisions"}],"predecessor-version":[{"id":44108,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/26481\/revisions\/44108"}],"wp:attachment":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/media?parent=26481"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/categories?post=26481"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/tags?post=26481"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}